

Appointment of Ms. Susan Knight and Mr. Stephen Denaro to the Board of Directors

MINNEAPOLIS, United States and BRISBANE, Australia 13 May 2026 (AEST): Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announces the appointment of Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board of Directors (the "Board").

Ms. Knight will serve as a Class I Director, with a term expiring at the Company's 2028 annual meeting of stockholders and will serve on the Audit and Risk Committee of the Board. Mr. Denaro will serve as a Class II Director, with a term expiring at the Company's 2026 annual meeting of stockholders.

Ms. Knight most recently served as the Board Chair of Surmodics, Inc., a medical device provider, a position she held from 2015 until November 2025. She has served on corporate boards of directors since 2008 and has broad audit committee experience, including serving as committee chair at Surmodics, Inc., Greater Metropolitan Housing Corporation and Plato Learning. During her professional career, Ms. Knight was the Senior Vice President and Chief Financial Officer of MTS Systems Corporation from 2011 to 2014 and its Chief Financial Officer from 2001 to 2011. Prior to MTS Systems Corporation, Ms. Knight was the Vice President of Finance of the Home and Building Control Business of Honeywell, Inc. from 1994 to 2001. She also held various other management and executive financial positions during her 24-year career at Honeywell, Inc. Ms. Knight earned a BSBA in Accounting from Creighton University.

Mr. Denaro rejoins the Board with deep knowledge of the Company and its strategic priorities.

There are no understandings or arrangements between Ms. Knight and Mr. Denaro and any other person pursuant to which Ms. Knight or Mr. Denaro was selected to serve as a director of the Company. There are no relationships between Ms. Knight and Mr. Denaro and the Company or any of its subsidiaries that would require disclosure pursuant to Item 404(a) of Regulation S-K.

As non-employee directors, each of Ms. Knight and Mr. Denaro will receive annual cash retainers, payable in monthly installments and prorated for any portion of a month that they are not serving in such positions on the Board or its committees in accordance with the Company's Non-Employee Director Compensation Policy (the "Policy"). Ms Knight will receive (A) on the date of her appointment, an initial equity grant consisting of restricted stock units ("RSUs") with an aggregate grant date fair value of \$250,000, which will vest in three substantially equal annual installments subject to her continued service on the Board through such dates and which grant will be subject to stockholder approval in accordance with the listing rules of the Australian Securities Exchange. Further, in accordance with the Policy, each Non-Employee Director (as defined in the Policy) who serves on the Board as of the date of any annual meeting and who continues to serve as a Non-Employee Director immediately following such annual meeting, is entitled to an annual equity grant consisting of RSUs with an aggregate grant date fair value of \$125,000. Notwithstanding the foregoing, the number of RSUs subject to the annual RSU award will be prorated if a Non-Employee Director has served on the Board for fewer than six months prior to the next annual meeting. Mr. Denaro will be entitled to equity awards with an aggregate grant date fair value of \$125,000 if he serves on the Board as of the date of an annual meeting and continues to serve as a Non-Employee Director immediately following such annual meeting. Mr. Denaro also serves as Company Secretary for a number of the Company's Australian subsidiary entities and is entitled to an annual fee of AUD \$57,645 for these services, paid in monthly instalments.



Effective May 11, 2026 (May 12, 2026 in Australia), the Company entered into indemnification agreements with each of Ms. Knight and Mr. Denaro in the form previously filed as Exhibit 10.2 to the Company's Form S-1 filed with the Securities and Exchange Commission on November 22, 2024. The indemnification agreement requires the Company to indemnify each of Ms. Knight and Mr. Denaro to the fullest extent permitted under Delaware law against liability that may arise by reason of their service to the Company, and to advance expenses incurred as a result of any proceedings against them as to which they could be indemnified, among other things.

ENDS

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR[®] Transcatheter Heart Valve ("THV"), was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR[®] THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR[®] THV is made using a single piece of molded ADAPT[®] tissue, Anteris' patented anti-calcification tissue technology. ADAPT[®] tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR[®] THV System is comprised of the DurAVR[®] valve, the ADAPT[®] tissue, and the balloon-expandable ComASUR[®] Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "budget," "target," "aim," "strategy," "plan," "guidance," "outlook," "may," "should," "could," "will," "would," "will be," "will continue," "will likely result" and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under "Risk Factors" in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Chief Executive Officer.



For more information:

Investor Relations

investors@anteristech.com

Debbie Ormsby

Anteris Technologies Global Corp.

+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

mchatterjee@bplifescience.com

Malini Chatterjee, Ph.D.

Blueprint Life Science Group

+1 917 330 4269

Website www.anteristech.com

X [@AnterisTech](#)

LinkedIn <https://www.linkedin.com/company/anteristech>

